Korean Post-marketing Surveillance Vyndamax® Capsules for the Treatment of Transthyretin Amyloid Cardiomyopathy

\*Inclusion Criteria: Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study: * 1\. Adult patients with the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) * 2\. Patients to whom Vyndamax® Capsules is prescribed for the treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) * 3\. Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study. * Exclusion criteria Patients meeting any of the following criteria will not be included in the study according to the local product label: * 1\. Patient with hypersensitivity or case history to tafamidis or to any of the excipients in the product * 2\. This product contains sorbitol (E420). Patients with rare hereditary problems of fructose intolerance should not take this medicine. * 3\. Patient who has a contraindication to Vyndamax® Capsules according to the approved local product label